PMCB PE Ratio & Valuation, Is PMCB Overvalued

Historical Valuation

PharmaCyte Biotech Inc (PMCB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.02. The fair price of PharmaCyte Biotech Inc (PMCB) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.68

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is PharmaCyte Biotech Inc (PMCB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

PharmaCyte Biotech Inc (PMCB) has a current Price-to-Book (P/B) ratio of 0.14. Compared to its 3-year average P/B ratio of 0.40, the current P/B ratio is approximately -64.72% higher. Relative to its 5-year average P/B ratio of 0.84, the current P/B ratio is about -83.15% higher. PharmaCyte Biotech Inc (PMCB) has a Forward Free Cash Flow (FCF) yield of approximately -60.49%. Compared to its 3-year average FCF yield of -24.53%, the current FCF yield is approximately 146.56% lower. Relative to its 5-year average FCF yield of -18.21%, the current FCF yield is about 232.08% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PMCB competitors is 0.09, providing a benchmark for relative valuation. PharmaCyte Biotech Inc Corp (PMCB.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PMCB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PMCB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PMCB currently overvalued or undervalued?

What is PharmaCyte Biotech Inc (PMCB) fair value?

PMCB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of PharmaCyte Biotech Inc (PMCB) is between to according to relative valuation method.

How does PMCB's valuation metrics compare to the industry average?

The average P/S ratio for PMCB's competitors is 0.09, providing a benchmark for relative valuation. PharmaCyte Biotech Inc Corp (PMCB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for PharmaCyte Biotech Inc (PMCB) as of Mar 12 2026?

As of Mar 12 2026, PharmaCyte Biotech Inc (PMCB) has a P/B ratio of 0.14. This indicates that the market values PMCB at 0.14 times its book value.

What is the current FCF Yield for PharmaCyte Biotech Inc (PMCB) as of Mar 12 2026?

As of Mar 12 2026, PharmaCyte Biotech Inc (PMCB) has a FCF Yield of -60.49%. This means that for every dollar of PharmaCyte Biotech Inc's market capitalization, the company generates -60.49 cents in free cash flow.

What is the current Forward P/E ratio for PharmaCyte Biotech Inc (PMCB) as of Mar 12 2026?

As of Mar 12 2026, PharmaCyte Biotech Inc (PMCB) has a Forward P/E ratio of -1.94. This means the market is willing to pay $-1.94 for every dollar of PharmaCyte Biotech Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for PharmaCyte Biotech Inc (PMCB) as of Mar 12 2026?

As of Mar 12 2026, PharmaCyte Biotech Inc (PMCB) has a Forward P/S ratio of 0.00. This means the market is valuing PMCB at $0.00 for every dollar of expected revenue over the next 12 months.

PMCB Valuation